Current status
FDA-approved peptide medicines, compounded products, and nominated bulk substances sit in different regulatory categories with different safety, quality, and eligibility questions.
FDA status table
| Record | Status | Peptides | What it means | Source events |
|---|---|---|---|---|
| BPC-157, KPV, TB-500, and MOTs-C bulk substances | Under Evaluation | BPC-157KPVTB-500MOTS-c | PCAC voted on July 23, 2026 to recommend these nominated substances for the 503A Bulks List: BPC-157, KPV, and TB-500 each passed 8-6 with one abstention, and MOTS-c passed 7-5 with two abstentions, all against FDA staff advice. The recommendations are non-binding; formal FDA rulemaking decides whether they join the list, so they are not yet eligible for 503A compounding. | PCAC MeetingPCAC Meeting |
| Emideltide/DSIP, Semax, and Epitalon bulk substances | Under Evaluation | DSIPSemaxEpitalon | PCAC voted on July 24, 2026 to recommend Semax (8-5, one abstention) and Epitalon (7-5, one abstention) for the 503A Bulks List, and voted 7-6 against emideltide (DSIP), the only negative recommendation of the seven-substance review. The recommendations are non-binding; FDA rulemaking follows, and none is yet eligible for 503A compounding. | PCAC MeetingPCAC Meeting |
| Safety and data gaps flagged by FDA | Risk Flagged | BPC-157KPVTB-500MOTS-cDSIPSemaxEpitalon | FDA's safety-risk page flags missing human exposure data, route-specific concerns, peptide-related impurities, immunogenicity, or other unresolved safety questions for multiple peptide-related bulk substances. | Safety Risk |
| Compounded semaglutide products | Risk Flagged | Semaglutide | FDA distinguishes approved semaglutide products from compounded semaglutide products and warns about dosing errors and quality concerns in compounded injectable products. | Consumer Warning |
| Approved tirzepatide product | Approval | Tirzepatide | FDA approval covers labeled tirzepatide use; it does not answer every research-market or compounded-product claim. | Approval |
Source events
- pcac meetingUS FDA
FDA PCAC meeting scheduled for selected peptide bulk substances
FDA scheduled July 23-24, 2026 PCAC discussions for BPC-157, KPV, TB-500, MOTs-C, emideltide/DSIP, Semax, and Epitalon bulk substances nominated for the 503A Bulks List.
- pcac meetingUS FDA
PCAC recommends six of seven nominated peptide bulk substances for the 503A Bulks List
PCAC voted on July 23-24, 2026 to recommend BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon for the 503A Bulks List, and voted 7-6 against emideltide (DSIP). All recommendations are non-binding; FDA rulemaking decides final list placement.
- safety riskUS FDA
FDA safety-risk page flags missing or limited safety information for several peptides
FDA lists potential safety and quality concerns for multiple nominated bulk drug substances, including peptide-related impurities, immunogenicity concerns, and missing human exposure data.
- consumer warningUS FDA
FDA distinguishes approved semaglutide products from compounded semaglutide risk
FDA describes approved semaglutide products and warns about dosing errors and quality concerns associated with compounded semaglutide products.
- approvalUS FDA
FDA approves Zepbound, a tirzepatide product, for chronic weight management
FDA approved Zepbound, containing tirzepatide, for chronic weight management in adults with obesity or overweight with at least one weight-related condition.
How to read FDA actions
An FDA meeting, warning, or docket entry can mean very different things. The important first step is knowing whether the source is an approval, warning, meeting notice, bulk-substance review, or safety-data gap. FDAFDA
Why compounded status is separated from approval
FDA explains that compounded drugs are not FDA-approved and that the agency does not verify their safety, effectiveness, or quality before marketing. Compounded and research-market products are not equivalent to FDA-approved medicines. FDA
Sources used
The source set uses FDA event pages, Federal Register or docket materials, approved-product labeling, and FDA compounding warnings. FDAFDAFDA
References
- 1.
FDA. Compounding and the FDA: Questions and Answers 2026.
Accessed 2026-06-08.
FDA explains that compounded drugs are not FDA-approved and that FDA does not verify their safety, effectiveness, or quality before marketing.
- 2.
FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee 2026.
Accessed 2026-07-24.
FDA meeting page for the July 23-24, 2026 PCAC review of BPC-157, KPV, TB-500, MOTs-C, emideltide/DSIP, Semax, and Epitalon bulk substances, including the uses evaluated for each, briefing documents, and docket FDA-2025-N-6895.
- 3.
Other. FDA Panel Finds a Peptide It Doesn't Like 2026.
Accessed 2026-07-24.
MedPage Today meeting recap with final PCAC vote counts: BPC-157, KPV, TB-500, and MOTS-c recommended on July 23; epitalon recommended 7-5 and semax recommended 8-5 on July 24, one abstention each; emideltide voted down 7-6 with one abstention.
- 4.
Other. FDA advisers vote against sleep peptide as they debate safety and health claims 2026.
Accessed 2026-07-24.
MarketWatch day-two report: emideltide (DSIP) fails 6-7 with one abstention, epitalon passes, member rationale quotes, and FDA staff concerns about 1980s-90s DSIP trial data.
- 5.
FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks 2026.
Accessed 2026-06-08.
FDA summarizes potential significant safety risks and missing safety information for several nominated peptide bulk substances.
- 6.
Accessed 2026-06-08.
FDA distinguishes approved semaglutide products from compounded semaglutide products and describes dosing-error concerns.
- 7.
FDA. FDA Approves New Medication for Chronic Weight Management 2023.
Accessed 2026-06-08.
FDA approval announcement for Zepbound, a tirzepatide product for chronic weight management in specified adults.